Arrowhead Pharmaceuticals, Inc. (ARWR) Balance Sheet

The rapid expansion of the balance sheet appears to be a function of capital raising and milestone recognition rather than organic asset growth. This suggests that the company's financial foundation remains highly sensitive to external funding events, which may indicate a lack of long-term structural stability.

The sharp increase in debt levels warrants further investigation into the company's long-term solvency, as the current reliance on leverage to fund operations may limit future financial flexibility. Investors should monitor whether this debt is sustainable given the absence of consistent, recurring cash flows from commercialized products.

While the current ratio of 6.23 might suggest a comfortable buffer, this metric is likely distorted by the timing of deferred revenue and short-term liabilities. The underlying cash burn rate implies that the company may need to pursue further dilutive financing to maintain its current R&D trajectory.